MAPT and Alzheimer disease: However, the current PET ligands lack demonstration of selectivity between Tau and TDP43 pathology, despite being sensitive to the burden and distribution of Tau pathology in FTD, progressive supranuclear palsy and Alzheimer’s disease (Bevan-Jones et al. 2017; Passamonti et al. 2017).